Drugs / Kivexa
Regulatory milestones approvals, filings & regulatory actions · 1 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Approved | EU (EMA) | Kivexa | — | 2004-12-16 | europa.eu ↗ |
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy3 trials | ||||||
| Phase 3 | NCT02486133 Comparator | Jul 2015 → May 2018 | HIV infectious disease | Technical University of Munich | Completed | No outcome recorded |
| Phase 4 | NCT02577042 Comparator | Oct 2015 → Jun 2018 | — | Fight AIDS and Infectious Diseases Foundation | Completed | No outcome recorded |
| Phase 4 | NCT00615810 Comparator | Mar 2008 → Oct 2009 | HIV infectious disease | Gilead Sciences | Completed | No outcome recorded |
Evidence & citations 1 cited value
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Kivexa | “Switching the PI by raltegravir 400mg every 12 hours, plus Kivexa or Truvada, for 24 weeks.” NCT02577042 ↗ |